Mevlüt Sait Keleş
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mevlüt Sait Keleş has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Uyanık
Department of Nephrology, Faculty of Medicine, Ataturk University, Erzurum, Turkey
2 shared publications - Ahmet Konrot
Speech and Language Therapy Department, Üsküdar University, Istanbul, Türkiye
2 shared publications - Bulent Aydinli
Akdeniz University Faculty of Medicine, Department of General Surgery, Antalya, Türkiye
2 shared publications - Erdem Çankaya
Faculty of Medicine, Department of Nephrology Atatürk University Erzurum Turkey
2 shared publications - Fatma Betül Özgeriş
Department of Nutrition and Dietetics, Faculty of Health Sciences, Atatürk University, Erzurum, Turkey
2 shared publications - Abdulgani Tatar
Department of Medical Genetics, Medical Faculty, Ataturk University, 25240 Erzurum, Turkey
1 shared publication
Latest Publications
- Open Access
Boron Compounds Exhibit Protective Effects against Aluminum-Induced Neurotoxicity and Genotoxicity: In Vitro and In Vivo Study
Genetic, neuropathological and biochemical investigations have revealed meaningful relationships between aluminum (Al) exposure and neurotoxic and hematotoxic damage. Hence, intensive efforts are being made to minimize the harmful effects of Al. Moreover, boron compounds are used in a broad mix of industries, from cosmetics and pharmaceuticals to agriculture. They affect critical biological functions in cellular events and enzymatic reactions, as well as endocrinal and mineral metabolisms. There are limited dose-related data about boric acid (BA) and other boron compounds, including colemanite (Col), ulexite (UX) and borax (BX), which have commercial prominence. In this study, we evaluate boron compounds’ genetic, cytological, biochemical and pathological effects against aluminum chloride (AlCl3)-induced hematotoxicity and neurotoxicity on different cell and animal model systems. First, we perform genotoxicity studies on in vivo rat bone marrow cells and peripheric human blood cultures. To analyze DNA and chromosome damage, we use single cell gel electrophoresis (SCGE or comet assay) and micronucleus (MN) and chromosome aberration (CA) assays. The nuclear division index (NDI) is used to monitor cytostasis. Second, we examine the biochemical parameters (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), total antioxidant capacity (TAC) and total oxidative status (TOS)) to determine oxidative changes in blood and brain. Next, we assess the histopathological alterations by using light and electron microscopes. Our results show that Al increases oxidative stress and genetic damage in blood and brain in vivo and in vitro studies. Al also led to severe histopathological and ultrastructural alterations in the brain. However, the boron compounds alone did not cause adverse changes based on the above-studied parameters. Moreover, these compounds exhibit different levels of beneficial effects by removing the harmful impact of Al. The antioxidant, antigenotoxic and cytoprotective effects of boron compounds against Al-induced damage indicate that boron may have a high potential for use in medical purposes in humans. In conclusion, our analysis suggests that boron compounds (especially BA, BX and UX) can be administered to subjects to prevent neurodegenerative and hematological disorders at determined doses.
Open AccessBoron Compounds Exhibit Protective Effects against Aluminum-Induced Neurotoxicity and Genotoxicity: In Vitro and In Vivo Study
Genetic, neuropathological and biochemical investigations have revealed meaningful relationships between aluminum (Al) exposure and neurotoxic and hematotoxic damage. Hence, intensive efforts are being made to minimize the harmful effects of Al. Moreover, boron compounds are used in a broad mix of industries, from cosmetics and pharmaceuticals to agriculture. They affect critical biological functions in cellular events and enzymatic reactions, as well as endocrinal and mineral metabolisms. There are limited dose-related data about boric acid (BA) and other boron compounds, including colemanite (Col), ulexite (UX) and borax (BX), which have commercial prominence. In this study, we evaluate boron compounds’ genetic, cytological, biochemical and pathological effects against aluminum chloride (AlCl3)-induced hematotoxicity and neurotoxicity on different cell and animal model systems. First, we perform genotoxicity studies on in vivo rat bone marrow cells and peripheric human blood cultures. To analyze DNA and chromosome damage, we use single cell gel electrophoresis (SCGE or comet assay) and micronucleus (MN) and chromosome aberration (CA) assays. The nuclear division index (NDI) is used to monitor cytostasis. Second, we examine the biochemical parameters (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), malondialdehyde (MDA), total antioxidant capacity (TAC) and total oxidative status (TOS)) to determine oxidative changes in blood and brain. Next, we assess the histopathological alterations by using light and electron microscopes. Our results show that Al increases oxidative stress and genetic damage in blood and brain in vivo and in vitro studies. Al also led to severe histopathological and ultrastructural alterations in the brain. However, the boron compounds alone did not cause adverse changes based on the above-studied parameters. Moreover, these compounds exhibit different levels of beneficial effects by removing the harmful impact of Al. The antioxidant, antigenotoxic and cytoprotective effects of boron compounds against Al-induced damage indicate that boron may have a high potential for use in medical purposes in humans. In conclusion, our analysis suggests that boron compounds (especially BA, BX and UX) can be administered to subjects to prevent neurodegenerative and hematological disorders at determined doses.
- 29 June 2022
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (2) , 298-303
Determining the Vasohibin-1 Levels of the Serum and Broncoalveolar Lavage Fluid in the Patients with Lung Cancer”
Objective: Lung cancer constitutes 17% of all cancer cases and accounts for 23% of the deaths caused by cancer all over the world. Vasohibin-1 (VASH-1) is an angiogenesis-inhibiting factor synthesized by endothelial cells (ECs). This study aimed to examine the VASH-1 levels of the bronchoalveolar lavage (BAL) and serum in the patients with lung cancer. Material and Method: A total of 82 patients participated in this study. 39 and 43 of them had a benign lung disease and lung cancer, respectively. The VASH-1 levels of serum and BAL were measured using the Enzyme-Linked Immunosorbent Assay (ELISA). Results: The BAL VASH-1 levels of the patients in the lung cancer group were found to be statistically significantly lower than those of the patients in the benign lung disease group (p=0.032). No statistically significant difference was found between the individuals with lung cancer and benign lung disease in terms of the serum VASH-1 concentration (p=0.206). A statistically significantly moderate positive correlation was found between the serum and BAL VASH-1 levels in the benign and malignant cases (benign r=0.442, p=0.005; malignant r=0.364, p=0.016). When the lung cancer patients were categorized into pathological stages and histological types, no significant difference was found between the stages and histological types in terms of the serum and BAL fluid VASH-1 concentrations. Conclusions: BAL VASH-1 concentrations decreased in the lung cancer patients compared to the individuals having a benign lung disease. Considering the results reached in this study, it was thought that the BAL VASH-1 concentrations might be beneficial in distinguishing between the benign and malignant lung diseases.
- 29 June 2022
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (2) , 298-303
Determining the Vasohibin-1 Levels of the Serum and Broncoalveolar Lavage Fluid in the Patients with Lung Cancer”
Objective: Lung cancer constitutes 17% of all cancer cases and accounts for 23% of the deaths caused by cancer all over the world. Vasohibin-1 (VASH-1) is an angiogenesis-inhibiting factor synthesized by endothelial cells (ECs). This study aimed to examine the VASH-1 levels of the bronchoalveolar lavage (BAL) and serum in the patients with lung cancer. Material and Method: A total of 82 patients participated in this study. 39 and 43 of them had a benign lung disease and lung cancer, respectively. The VASH-1 levels of serum and BAL were measured using the Enzyme-Linked Immunosorbent Assay (ELISA). Results: The BAL VASH-1 levels of the patients in the lung cancer group were found to be statistically significantly lower than those of the patients in the benign lung disease group (p=0.032). No statistically significant difference was found between the individuals with lung cancer and benign lung disease in terms of the serum VASH-1 concentration (p=0.206). A statistically significantly moderate positive correlation was found between the serum and BAL VASH-1 levels in the benign and malignant cases (benign r=0.442, p=0.005; malignant r=0.364, p=0.016). When the lung cancer patients were categorized into pathological stages and histological types, no significant difference was found between the stages and histological types in terms of the serum and BAL fluid VASH-1 concentrations. Conclusions: BAL VASH-1 concentrations decreased in the lung cancer patients compared to the individuals having a benign lung disease. Considering the results reached in this study, it was thought that the BAL VASH-1 concentrations might be beneficial in distinguishing between the benign and malignant lung diseases.
- 11 March 2022
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 87 (3) , 207-214
High Serum Progranulin Levels in COVID-19 Patients: A Pilot Study
In this study, we aimed to determine whether the progranulin level in serum predicts the course and severity of the disease in COVID-19 (+) patients and whether it can be used as a biomarker in these patients. Therefore, we sampled 61 people infected with COVID-19, and the cases were divided into the following groups: asymptomatic, noncomplicated, moderate, and severe. Concentrations of progranulin, TNF-α, IL-6 from in serum obtained from all participants were measured using commercially available ELISA kits, as well as WBC, PLT, NE, LY, ALT, AST, Hb, PCT, and CRP were examined with clinical analyzer. All measurements obtained for the patient samples were compared with those of 20 healthy individuals. The serum progranulin concentration was statistically higher in the COVID-19 (+) patient group than in the control group of healthy individuals [112.6 ± 54.8, 0.0 (0.0-54.2 pg/ml, respectively p = 0.000)]. ROC analysis was performed to evaluate the progranulin potential as a biomarker for COVID-19 (+) patients. A larger AUC (0.931 ± 0.08) value and a more significant p-value for progranulin than for CRP (p = 0.000) was detected. As a result, we believe that progranulin reaches high levels in the COVID-19 disease and may be a determinant in diagnosis and prognosis, and may be a better biomarker than CRP.
- 11 March 2022
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 87 (3) , 207-214
High Serum Progranulin Levels in COVID-19 Patients: A Pilot Study
In this study, we aimed to determine whether the progranulin level in serum predicts the course and severity of the disease in COVID-19 (+) patients and whether it can be used as a biomarker in these patients. Therefore, we sampled 61 people infected with COVID-19, and the cases were divided into the following groups: asymptomatic, noncomplicated, moderate, and severe. Concentrations of progranulin, TNF-α, IL-6 from in serum obtained from all participants were measured using commercially available ELISA kits, as well as WBC, PLT, NE, LY, ALT, AST, Hb, PCT, and CRP were examined with clinical analyzer. All measurements obtained for the patient samples were compared with those of 20 healthy individuals. The serum progranulin concentration was statistically higher in the COVID-19 (+) patient group than in the control group of healthy individuals [112.6 ± 54.8, 0.0 (0.0-54.2 pg/ml, respectively p = 0.000)]. ROC analysis was performed to evaluate the progranulin potential as a biomarker for COVID-19 (+) patients. A larger AUC (0.931 ± 0.08) value and a more significant p-value for progranulin than for CRP (p = 0.000) was detected. As a result, we believe that progranulin reaches high levels in the COVID-19 disease and may be a determinant in diagnosis and prognosis, and may be a better biomarker than CRP.
- 1 June 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (5) , 1425-1428
Changes in Exfoliative Cell of Oral Mucosa in Kidney Transplant Patients
- 1 June 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (5) , 1425-1428
Changes in Exfoliative Cell of Oral Mucosa in Kidney Transplant Patients
- 1 June 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (5) , 1302-1305
Effect of Kidney Transplantation on Smoking Habits of Kidney Donors
- 1 June 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (5) , 1302-1305
Effect of Kidney Transplantation on Smoking Habits of Kidney Donors
- Open Access
- 1 August 2014
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 8, 1573-8
Evaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration
Evaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration Sadullah Keles,1 Orhan Ates,1 Baki Kartal,2 Hamit Hakan Alp,3 Metin Ekinci,4 Erdinc Ceylan,2 Osman Ondas,5 Eren Arpali,2 Semih Dogan,6 Kenan Yildirim,7 Mevlut Sait Keles8 1Department of Ophthalmology, School of Medicine, Ataturk University, Erzurum, Turkey; 2Department of Ophthalmology, Regional Training and Research Hospital, Erzurum, Turkey; 3Department of Biochemistry, School of Medicine, Yuzuncu Yil University, Van, Turkey; 4Department of Ophthalmology, School of Medicine, Kafkas University, Kars, Turkey; 5Department of Ophthalmology, Erbaa Government Hospital, Tokat, Turkey; 6Department of Ophthalmology, Kolan Hospital, Istanbul, Turkey; 7Department of Ophthalmology, Igdir Government Hospital, Igdir, Turkey; 8Department of Biochemistry, School of Medicine, Ataturk University, Erzurum, Turkey Aim: To evaluate levels of homocysteine, asymmetric dimethylarginine (ADMA), and nitric oxide (NO), as well as activity of endothelial NO synthase (eNOS), in patients with age-related macular degeneration (AMD).Methods: The levels of homocysteine, ADMA, and NO and activity of eNOS in patients who were diagnosed with wet AMD by fundus fluorescein angiography (n=30) were compared to a control group with no retinal pathology (n=30).Results: Levels of homocysteine and ADMA were found to be significantly higher in the wet AMD group than in the control group (P<0.001), whereas NO levels and eNOS activity were higher in the control group (P<0.001). In the wet AMD group, we detected a 2.64- and 0.33-fold increase in the levels of ADMA and homocysteine, respectively, and a 0.49- and 2.41-fold decrease in the eNOS activity and NO level, respectively.Conclusion: Elevated levels of homocysteine and ADMA were observed in patients with wet AMD. Increased ADMA may be responsible for the diminished eNOS activity found in these patients, which in turn contributes to the decrease in NO levels, which likely plays a role in the pathogenesis of AMD. Keywords: age-related macular degeneration, homocysteine, asymmetric dimethylarginine, nitric oxide, endothelial nitric oxide synthase activity
- 1 August 2014
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 8, 1573-8
Open AccessEvaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration
Evaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration Sadullah Keles,1 Orhan Ates,1 Baki Kartal,2 Hamit Hakan Alp,3 Metin Ekinci,4 Erdinc Ceylan,2 Osman Ondas,5 Eren Arpali,2 Semih Dogan,6 Kenan Yildirim,7 Mevlut Sait Keles8 1Department of Ophthalmology, School of Medicine, Ataturk University, Erzurum, Turkey; 2Department of Ophthalmology, Regional Training and Research Hospital, Erzurum, Turkey; 3Department of Biochemistry, School of Medicine, Yuzuncu Yil University, Van, Turkey; 4Department of Ophthalmology, School of Medicine, Kafkas University, Kars, Turkey; 5Department of Ophthalmology, Erbaa Government Hospital, Tokat, Turkey; 6Department of Ophthalmology, Kolan Hospital, Istanbul, Turkey; 7Department of Ophthalmology, Igdir Government Hospital, Igdir, Turkey; 8Department of Biochemistry, School of Medicine, Ataturk University, Erzurum, Turkey Aim: To evaluate levels of homocysteine, asymmetric dimethylarginine (ADMA), and nitric oxide (NO), as well as activity of endothelial NO synthase (eNOS), in patients with age-related macular degeneration (AMD).Methods: The levels of homocysteine, ADMA, and NO and activity of eNOS in patients who were diagnosed with wet AMD by fundus fluorescein angiography (n=30) were compared to a control group with no retinal pathology (n=30).Results: Levels of homocysteine and ADMA were found to be significantly higher in the wet AMD group than in the control group (P<0.001), whereas NO levels and eNOS activity were higher in the control group (P<0.001). In the wet AMD group, we detected a 2.64- and 0.33-fold increase in the levels of ADMA and homocysteine, respectively, and a 0.49- and 2.41-fold decrease in the eNOS activity and NO level, respectively.Conclusion: Elevated levels of homocysteine and ADMA were observed in patients with wet AMD. Increased ADMA may be responsible for the diminished eNOS activity found in these patients, which in turn contributes to the decrease in NO levels, which likely plays a role in the pathogenesis of AMD. Keywords: age-related macular degeneration, homocysteine, asymmetric dimethylarginine, nitric oxide, endothelial nitric oxide synthase activity